[Treatment of respiratory syncytial virus by intravenous gamma-globulin].

AIM: To explore in vitro and in vivo the effect of the intravenous gamma-globulin (IVgammaG) on the respiratory syncytial virus (RSV). METHODS: (1) The microdose cytopathogenic inhibition assay (MCIA) was used to observe the effect of different concentrations of IVgammaG on RSV replication. (2) 40 BALB/c mice were infected with RSV and then randomly divided into four groups: namely, the IVgammaG treatment group, the ribavirin treatment group, the Palivizumab treatment group and the normal saline group (control group). Half of the mice in each group were killed at the fifth day and the seventh day after treatment, respectively, to isolate the virus and perform pathological examination of the lung tissue. RESULTS: (1) IVgammaG inhibited RSV replication in vitro. The treatment index (TI) of IVgammaG was 275, which was about 7 times of TI of ribavirin and one third of Palivizumab. (2) The pathological score of the lung tissue in the IVgammaG group was lower than that of control group (P<0.01), but higher than that of Palivizumab group (P<0.05). CONCLUSION: The IVgammaG has an anti-RSV effect both in vivo and in vitro, but its effect is lower than that of Palivizumab.